MVA as a vector for vaccines against HIV-1
| Autor: | Tomáš Hanke, Eung-Jun Im |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
viruses
Immunology Human immunodeficiency virus (HIV) Vaccinia virus medicine.disease_cause complex mixtures Virus Viral vector chemistry.chemical_compound Drug Discovery Medicine Animals Humans Vector (molecular biology) Smallpox vaccine Pharmacology AIDS Vaccines Clinical Trials as Topic business.industry virus diseases Prime boost Virology chemistry HIV-1 Molecular Medicine Vaccinia business |
| Popis: | A vaccine against HIV Type 1 (HIV-1) is urgently needed. Modified vaccinia virus Ankara is an attenuated smallpox vaccine which can be adapted to express HIV-1 antigens. In this review, we discuss the features which make modified vaccinia virus Ankara an attractive vector for genetic vaccines and have put it, together with several other recombinant viral vectors, at the forefront of HIV-1 vaccine development. Many candidate vaccines including those vectored by modified vaccinia virus Ankara are now entering human trials, the results of which will become available in the coming years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|